Actively Recruiting

Phase 4
Age: 18Years +
All Genders
NCT04240834

Ticagrelor With Low-dose Versus Regular Aspirin in Patients With Acute Coronary Syndrome (ACS) at High-Risk for Ischemia After Percutaneous Coronary Intervention

Led by Fu Wai Hospital, Beijing, China · Updated on 2024-06-18

1220

Participants Needed

1

Research Sites

304 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The present study is aimed to compare the safety and efficacy of Ticagrelor with low-dose Aspirin versus standard dual anti-platelet therapy (DAPT) in patients with acute coronary syndrome (ACS) at high risk for ischemic events after percutaneous coronary intervention (PCI) and stent implantation.

CONDITIONS

Official Title

Ticagrelor With Low-dose Versus Regular Aspirin in Patients With Acute Coronary Syndrome (ACS) at High-Risk for Ischemia After Percutaneous Coronary Intervention

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • ACS patients at high risk for ischemic events after successful PCI with implantation of at least one drug eluting stent
  • Able and willing to provide informed consent and participate in 12 months follow-up period
  • Able to receive DAPT treatment
  • Must meet at least one angiographic or clinical inclusion criteria
  • Family history of premature coronary heart disease (male relative <55 years or female relative <65 years)
  • Repeated myocardial infarction
  • Positive serum cardiac troponin I/T
  • Combined with at least one organ/system with atherosclerotic disease (e.g. intracranial or peripheral arteries)
  • Type 2 diabetes mellitus under medication
  • Chronic kidney disease (eGFR<60 mL/min/1.73 m2 or CrCl<60ml/min)
  • LM lesion requiring stents
  • Proximal LAD lesion(s) requiring stents
  • Bypass grafts lesion(s) requiring stents
  • Overall stent length ≥60 mm
  • History of in-stent thrombosis
  • Bifurcation lesions requiring at least 2 stents
  • Over two vessels lesions requiring stents
  • Calcified target lesion(s) requiring atherectomy
  • The intraoperative occurrence of no-reflow or slow-flow
  • Compressed branch vessels with diameter ≥2.0 mm failing to restore flow (at least TIMI 3)
Not Eligible

You will not qualify if you...

  • Need for chronic oral anticoagulation
  • Cardiomyopathy (HCM, DCM, RCM)
  • Severe ventricular arrhythmia requiring ICD implantation
  • Chronic respiratory disease (COPD, asthma, chronic bronchitis, pulmonary heart disease)
  • Severe infectious disease (active hepatitis B, active hepatitis C, AIDS)
  • Hematological disorders (thrombocytopenia, severe anemia, leukemia)
  • Severe liver disease or kidney failure
  • Malignant tumor
  • Cognitive impairment
  • Unable or unwilling to provide informed consent or undergo follow-up

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Fuwai Hospital

Beijing, Beijing Municipality, China

Actively Recruiting

Loading map...

Research Team

H

Haiyan Qian, MD, PhD

CONTACT

Z

Zhiyao Wei

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here